Feasibility and attractiveness of indication value-based pricing in key EU countries.
Feasibility and attractiveness of indication value-based pricing in key EU countries.
复制标题
DOI：
10.3402/jmahp.v4.30970
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Payers’ Insight
中科院分区：
文献类型：
--
作者：
Flume M;Bardou M;Capri S;Sola-Morales O;Cunningham D;Levin LA;Touchot N;Payers’ Insight
在美国，已经提出了以适应症价值为基础的定价（IBP），作为一种工具来获取药物在适应症或患者群体之间的差异价值，目前正处于实施的早期阶段。在欧洲，没有一个主要国家试验过IBP或正在认真讨论其使用。我们评估了七个欧洲国家的补偿和定价环境如何允许IBP，评估了激励措施和障碍。在法国和德国等定价国家，卫生技术评估和定价过程已经考虑到了不同适应症的价值差异。在英国和瑞典等差别价值驱动覆盖决策的国家，有创血压可能会被使用，至少是部分使用，但短期内不会。意大利已经通过管理入境协议实现了某种形式的差别价值，而在西班牙，电子处方系统为IBP提供了必要的基础设施，但还存在其他障碍。
Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experimented with IBP or is seriously discussing its use. We assessed how the reimbursement and pricing environment allows for IBP in seven European countries, evaluating both incentives and hurdles. In price setting countries such as France and Germany, the Health Technology Assessment and pricing process already accounts for differences of value across indications. In countries where differential value drives coverage decisions such as the United Kingdom and Sweden, IBP is likely to be used, at least partially, but not in the short-term. Italy is already achieving some form of differential value through managed entry agreements, whereas in Spain the electronic prescription system provides the infrastructure necessary for IBP but other hurdles exist.